This Phase 2 randomized study is designed to evaluate dapansutrile’s efficacy and safety in approximately 300 patients with elevated blood glucose, systemic inflammation and at risk for complications of diabetes, despite use of standard-of-care anti-diabetic therapy
We are pleased to announce that the clinical trial of INTERCEPT-T2D has officially begun; under the sponsorship of the Clinical Trials Unit at University Hospital Basel (USB).
Participating Clinical Centres
Recruitment is underway at five leading European centres since June 27th :
• University Hospital of Basel
• Swiss university and major hospitals (HUG, CHUV, KSA, USZ, LUKS, KSSG)
• AP-HP, Paris (Groupe Hospitalier Bichat – Claude Bernard; Hôpital Lariboisière; Hôpital Cochin)
• Centre Hospitalier Universitaire de Liège
• German Diabetes Center
Each site is recruiting patients from their established outpatient clinics. To ensure efficient enrollment, monthly recruitment dashboards, hotline support for investigators, and bimonthly tele-conferences will be used to address any barriers in real time.
Next Steps
Over the next two years, we will continue patient screening, capture all study data, and conduct interim data reviews.
We thank all partners and participants for their dedication to this effort.